Further systematic exome-wide comparisons between affected and unaffected BRCA1/2 heterozygotes, or between young-onset and late-onset BRCA1/2-driven cancer cases, are required to reveal novel genetic determinants which influence cancer risk BRCA1/2 mutation carriers. The gene discussed is BRCA1; the disease is cancer.